Precipio

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Precipio (PRPO) reports revenue growth and aims for profitability

Precipio's Q2 performance reflects positive momentum in revenue growth and operational improvements. While challenges like achieving profitability and FDA approval exist, the company's focus on building relationships and scaling up presents opportunities for future growth. Overall, Precipio is well-positioned to achieve its goals and enhance investor relations post-profitability.

Precipio (PRPO) achieves record diagnoses, nears breakeven in Q3 2024

Precipio's Q3 2024 earnings call highlights strong revenue growth, progress towards breakeven, and improved financial stability. While facing challenges in investor relations, the company's focus on education and visibility initiatives shows a proactive approach to addressing concerns. Leveraging key customer relationships and sustainable growth strategies offer promising opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) today announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the company's common stock in order to regain compliance with the Nasdaq minimum bid price requirement of $1.00.

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces its Pathology Division has in August exceeded the monthly breakeven revenue goal which, if continued, causes this division to contribute cash to the Company's operations.

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Precipio, Inc. (NASDAQ:PRPO ) Q2 2023 Earnings Conference Call August 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Second Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.

Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript

NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET.

Precipio Announces Q2-2023 Shareholder Update Call

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

These efficiencies plus revenue growth expected to continue the positive momentum These efficiencies plus revenue growth expected to continue the positive momentum

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Revenue growth and customer pipeline advance the Company towards breakeven Revenue growth and customer pipeline advance the Company towards breakeven

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling

Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

New panel will enable rapid, precise genetic profiling of patients with deadly disease New panel will enable rapid, precise genetic profiling of patients with deadly disease

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000 shares of the Company's common stock and pre-funded warrants to purchase 319,445 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 8,888,890 shares of common stock at a combined purchase price of $0.45 in a concurrent private placement (together with the registered direct offering, the “offering”). The pre-funded warrants will have a nominal exercise price of $0.001 per share and will be immediately exercisable and of indefinite term. The common warrants issued pursuant to the concurrent private placement will have an exercise price of $0.63 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date.

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3 Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

Precipio, Inc. (NASDAQ:PRPO ) Q1 2023 Earnings Conference Call May 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Q1 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.

Precipio, Inc. (PRPO) Q1 2023 Earnings Call Transcript

NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , will be discussing on today's shareholders call several growth catalysts that management has been tracking.

Precipio Shares Growth Catalysts For HemeScreen

NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET.

Precipio Announces Q1-2023 Shareholder Update Call

Customer's pathology services annual revenues expected to exceed $1.5M Customer's pathology services annual revenues expected to exceed $1.5M

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory.

Precipio Signs Another HemeScreen™ Customer

Extension will enable the Company to execute on its growth and advance toward breakeven Extension will enable the Company to execute on its growth and advance toward breakeven

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

Q1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022 Q1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

Precipio, Inc. (NASDAQ:PRPO ) Q4 2022 Earnings Conference Call April 3, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio shareholder 2022 Fourth Quarter and Year-End Shareholder Update Conference Call. All participants will be in listen-only mode.

Precipio, Inc. (PRPO) Q4 2022 Earnings Call Transcript

Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ET Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ET

Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

Products Division revenues begin to diversify beyond HemeScreen® Products Division revenues begin to diversify beyond HemeScreen®

Precipio Ships First IV-Cell® Order to Major US Healthcare System

Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growth Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growth

CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers

Precipio continues to sign up and onboard HemeScreen™ customers

HemeScreen® Technology and Product Line singled out from thousands of products distributed by Fisher Healthcare at recent National Sales Meeting HemeScreen® Technology and Product Line singled out from thousands of products distributed by Fisher Healthcare at recent National Sales Meeting

News for Precipio Stock (PRPO)